GILD's 10Q doesnt sound quite so bullish compared to the CFO's comments. Like I said, a tall order for the junior party(Gilead) to win in these cases.
-----------
"Our patent covers metabolites of GS-7977 and RG7128. Idenix is attempting to claim a class of compounds including these metabolites in their pending patent application. In the course of this proceeding, both parties will be called upon to submit evidence of the date they conceived of their respective inventions. The Interference will determine who was first to invent these compounds and therefore who is entitled to the patent claiming these compounds. If the administrative law judge determines Idenix is entitled to these patent claims and it is determined that we have infringed those claims, we may be required to obtain a license from, and pay royalties to, Idenix to commercialize GS-7977 and RG7128."
Market Data 
Markets 
AI
